Zydus Lifesciences Limited

Zydus Lifesciences Limited

Zydus Lifesciences Limited has incorporated a wholly owned subsidiary, Zydus Global Treasury Centre IFSC Limited, in Gandhinagar, Gujarat.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has informed the Exchange about General Updates, disclosing an improvement in its ESG (Environment, Social, and Governance) score from 61 to 66, as per CRISIL Ratings Limited's report dated August 24, 2026.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has made a disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015, regarding the transmission of 32,577 equity shares from Late Jasodaben Babubhai Patel to Prashant Babubhai Patel, a member of the promoter group.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has informed the Exchange about Investor Presentation for investor conference between August 24, 2026, to August 26, 2026.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has informed the Exchange about General Updates, disclosing an ESG rating of 60 from ESGRAIL, a SEBI registered ESG Rating Provider, based on publicly available information.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has received final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Ascorbic Acid Injection, a generic equivalent of Ascor Injection, with 180-Days CGT exclusivity.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has informed the Exchange about the transcript of the post-results earnings call held on August 11, 2026. The company's Q1 FY27 financial performance was robust with a 22% year-on-year growth in consolidated revenues and an EBITDA margin of 24.1%. The net profit for the quarter stood at ₹ 9.4 billion. The company's branded formulations business in India sustained market outperformance with a strong 20% year-on-year growth during the quarter.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has informed the Exchange about a scheduled investor conference in Singapore and Hong Kong between August 24, 2026, to August 26, 2026.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has rescheduled its participation in the Motilal Oswal 22nd Annual Global Investor Conference to August 17, 2026, from the previously announced date of August 18, 2026.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has published unaudited financial results for the quarter ended June 30, 2026, in accordance with SEBI regulations.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has informed the Exchange regarding the re-appointment of Dr. Sharvil P. Patel as the Managing Director for a further period of five years and the appointment of Mr. Kulin S. Lalbhai as an Independent Director for a term of five years.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 11, 2026. The company has submitted the Exchange a copy of Scrutinizers report along with voting results.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has informed the Exchange about the availability of the audio recording of the Company's Investor Call discussing the unaudited financial results for the quarter ended on June 30, 2026, on the Company's website.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has reported a violation of the SEBI (Prohibition of Insider Trading) Regulations, 2015, by one of its Designated Persons, Mr. Ashutosh Patil, who traded in the company's equity shares without adhering to the Code of Conduct.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has entered into an option and license agreement with Mereo BioPharma for the U.S. commercial and global manufacturing rights to alvelestat for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD).

Zydus Lifesciences Limited

Zydus Lifesciences Limited has announced its unaudited financial results for Q1 FY27, with revenue from operations at Rs. 80,170 mn, up 22% over last year. EBITDA for the quarter was Rs. 19,294 mn, down 8% y-o-y, and net profit was Rs. 9,398 mn, down 36% y-o-y. The company has also provided business-wise sales performance and key highlights for the quarter.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has informed the Exchange about Investor Presentation for Q1 FY27, with total revenues growing 22% YoY and highlights of Q1 FY27 including R&D and operations.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at INR 27,235 million.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has launched REVAHALE, India's first once-daily nebulised LAMA for COPD, offering sustained 24-hour bronchodilation through convenient nebulised delivery.

Zydus Lifesciences Limited

Zydus Lifesciences Limited has informed the Exchange about participating in the Motilal Oswal 22nd Annual Global Investor Conference on August 18, 2026.